Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
Saved in:
| Title: | Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial. |
|---|---|
| Authors: | Cramer P; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany. Electronic address: paula.cramer@uk-koeln.de., Fürstenau M; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Robrecht S; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Giza A; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Zhang C; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Fink AM; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Fischer K; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Langerbeins P; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Al-Sawaf O; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Tausch E; Department of Internal Medicine III, Division of CLL, University Hospital Ulm, Ulm, Germany., Schneider C; Department of Internal Medicine III, Division of CLL, University Hospital Ulm, Ulm, Germany., Schetelig J; Department I of Internal Medicine, University Hospital Carl Gustav Carus, Dresden, Germany., Dreger P; Department V of Internal Medicine, University Hospital Heidelberg, Heidelberg, Germany., Böttcher S; Clinic for Internal Medicine III (Hematology, Oncology, Palliative Care), Rostock University Medical School, Rostock, Germany., Kreuzer KA; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Schilhabel A; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany., Ritgen M; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany., Brüggemann M; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany., Kneba M; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany., Stilgenbauer S; Department of Internal Medicine III, Division of CLL, University Hospital Ulm, Ulm, Germany., Eichhorst B; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Hallek M; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany. |
| Source: | The Lancet. Haematology [Lancet Haematol] 2022 Oct; Vol. 9 (10), pp. e745-e755. Date of Electronic Publication: 2022 Aug 18. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
